Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTH120 in Adult Males With Fragile X Syndrome
NCT07654114Phase 2Recruiting
- Sponsor
- CONNECTA Therapeutics
- Start
- May 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of CTH120 in Fragile X syndrome (FXS), sponsored by CONNECTA Therapeutics. Started May 2026; status: recruiting.
02
Drugs
CTH120
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT07654114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654114.